In some trials in United States of America (USA) and Bangladesh, vasodilating non selective β blockers (e.g. carvedilol, propranolol etc.) have been shown to be better tolerated than non- vasodilating β1 selective blocker (e.g. atenolol, metoprolol etc.) to prevent cardiovascular diseases (Coronary Heart Disease, Ischemic Heart Disease and other cardiovascular conditions)